Cancer Institute A national cancer institute
designated cancer center

Philip W. Lavori

Publication Details

  • Description of antipanic therapy in a prospective longitudinal study JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY Yonkers, K. A., Ellison, J. M., Shera, D. M., Pratt, L. A., Cole, J. O., FIERMAN, E., Keller, M. B., Lavori, P. W. 1996; 16 (3): 223-232

    Abstract:

    The authors present a summary scale for assessing the percentage of patients in a large longitudinal study of panic disorder who received proven effective psychopharmacologic treatment. Such a scale provides a means for assessing and comparing somatic treatments of panic disorder across medication classes. The antipanic therapy levels were applied to data on medication treatment received by 492 patients participating in a naturalistic study and reflect psychopharmacologic treatment prescribed in 11 academic centers. Results show that among patients treated by psychiatrists at major teaching hospitals only 54% of the most symptomatic groups received optimal pharmacologic treatment. Among less symptomatic patients, who nonetheless met full criteria for panic disorder with or without agoraphobia, only 43% received maximal therapy.

    View details for Web of Science ID A1996UR18400006

    View details for PubMedID 8784654

Stanford Medicine Resources:

Footer Links: